Day One Biopharmaceuticals, Inc. Common Stock (DAWN) is a publicly traded Healthcare sector company. As of May 21, 2026, DAWN trades at $21.53 with a market cap of $2.22B and a P/E ratio of -20.70. DAWN moved +0.14% today. Year to date, DAWN is +158.15%; over the trailing twelve months it is +193.72%. Its 52-week range spans $5.64 to $21.53. Analyst consensus is buy with an average price target of $23.75. Rallies surfaces DAWN's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
DAWN financials on Rallies include revenue, net income, EPS, valuation metrics, market cap, price history, and balance sheet context. DAWN recently traded at $21.53. Market cap is $2.22B. P/E ratio is -20.70. Revenue is $158.18M.
| Metric | Value |
|---|---|
| Price | $21.53 |
| Market Cap | $2.22B |
| P/E Ratio | -20.70 |
| EPS | $-1.04 |
| Dividend Yield | 0.00% |
| 52-Week High | $21.53 |
| 52-Week Low | $5.64 |
| Volume | 2.99M |
| Avg Volume | 0 |
| Revenue (TTM) | $158.18M |
| Net Income | $-107.32M |
| Gross Margin | 0.00% |
| Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $158.18M | $-107.32M | $-1.04 |
| 2024 | $131.16M | $-7.14M | $-1.02 |
| 2023 | $0 | $-188.92M | $-2.37 |
| 2022 | $4.75M | $-142.18M | $-2.17 |
12 analysts cover DAWN: 0 strong buy, 6 buy, 6 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $23.75.